Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2014-06-16

FDA Approved: PROLIA — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental labeling application for PROLIA (denosumab) submitted by Amgen to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Prolia (denosumab)

Snippet

SUPPL AP for PROLIA (DENOSUMAB)